Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis ...

Suggested remit: To appraise the clinical and cost effectiveness of Darolutamide with androgen within its marketing authorisation for treating prostate cancer.

Triple therapy with darolutamide vs abiraterone for metastatic hormone-sensitive prostate cancer is associated ... Although the pivotal phase 3 ARASENS trial demonstrated that patients with ...

The approval comes after the presentation of data from the ARASENS ... (ANVISA)). Darolutamide is also being investigated in further studies across various stages of prostate cancer.

Bayer is also developing darolutamide in metastatic hormone-sensitive prostate cancer, where the phase 3 prostate cancer trial ARASENS is testing its safety and efficacy. Scott Fields, senior vice ...

Subgroup analyses from the investigational Phase III ARASENS trial ... in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase ...

New subgroup analysis from the investigational Phase III ARANOTE trial show that NUBEQA ® (darolutamide ... volume metastatic hormone-sensitive prostate cancer (mHSPC), compared to placebo ...

New subgroup analysis from the investigational Phase III ARANOTE trial show that NUBEQA ® (darolutamide ... with high and low-volume metastatic hormone-sensitive prostate cancer (mHSPC), compared to ...

“Darolutamide is establishing itself as a key therapy in the treatment of prostate cancer, a market worth approximately $12bn in 2023. “If the addition of opaganib can reduce the resistance to ...

Darolutamide plus ADT vs placebo plus ADT improves oncologic outcomes in patients with mHSPC regardless of disease volume, although the benefit is more pronounced among patients with low-volume ...